Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Active Biotech presents positive cancer drug data
By step-wise dose escalation, a safe dose of 1mg/day of TASQ was achieved, which corresponds to a doubling of the previously reported maximum tolerated dose level of 0.5mg/day.
By step-wise dose escalation, a safe dose of 1mg/day of TASQ was achieved, which corresponds to a doubling of the previously reported maximum tolerated dose level of 0.5mg/day.
SCOLR Pharma had previously announced a research collaboration with an undisclosed US-based biopharmaceutical company in September 2006. Peramivir is being developed by BioCryst and is part of a
The Stanford work raises the possibility that humans could make use of this immune response if their immune system compromised. The evidence shows that a fruit fly’s immune
The research examined 20 studies on the effects of statins that covered 828 patients. Of those studies, 291 patients were given statins, 272 were given a placebo and
There are two major strains of malaria effecting humans, P. vivax and P. falciparum. Although attention focuses on the more virulent P. falciparum, vivax malaria causes a huge
A court previously ruled that Abbott was prohibited from any further sales, use or export of products, including components that infringe on Innogenetics’ patent on its hepatitis C
Basilea plans to sell up to 1.15 million new shares, one new share for each five existing shares held. The company said it had an option to offer
Teva said shipment of the cabergoline tablets, which have been cleared for 0.5mg strength, will begin immediately. Total annual sales of this product in the US, including brand
The Department of Health & Human Services (HHS) said the product was no longer in the competitive range for the Request for Proposal (RFP). Hollis-Eden Pharmaceuticals said it
The clinical trial is designed to evaluate the safety, tolerability and efficacy of AT-1001 in 86 subjects during gluten challenge. Patients were randomized into seven drug-treated and placebo